Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1984 1
1986 1
1991 1
1993 1
1995 1
1997 1
2003 1
2008 1
2015 2
2016 1
2017 1
2018 1
2019 1
2020 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Recent clinical trials with levamisole.
Kurman MR. Kurman MR. Ann N Y Acad Sci. 1993 Jun 23;685:269-77. doi: 10.1111/j.1749-6632.1993.tb35875.x. Ann N Y Acad Sci. 1993. PMID: 8363230 Review. No abstract available.
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.
Phillips AA, Fields PA, Hermine O, Ramos JC, Beltran BE, Pereira J, Wandroo F, Feldman T, Taylor GP, Sawas A, Humphrey J, Kurman M, Moriya J, Dwyer K, Leoni M, Conlon K, Cook L, Gonsky J, Horwitz SM; 0761-009 Study Group. Phillips AA, et al. Among authors: kurman m. Haematologica. 2019 May;104(5):993-1003. doi: 10.3324/haematol.2018.205096. Epub 2018 Dec 20. Haematologica. 2019. PMID: 30573506 Free PMC article. Clinical Trial.
Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes.
Garcia-Manero G, Pemmaraju N, Alvarado Y, Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A, Mukherjee S, Gerds A, Carraway HE, Nazha A, Iwamura H, Murase M, Bavisotto L, Kurman M, Maier G, Johansen M, Sekeres MA. Garcia-Manero G, et al. Among authors: kurman m. Leuk Lymphoma. 2020 Aug;61(8):1943-1953. doi: 10.1080/10428194.2020.1747065. Epub 2020 Apr 7. Leuk Lymphoma. 2020. PMID: 32264726 Clinical Trial.
Levamisole and melanoma.
Kurman MR. Kurman MR. J Clin Oncol. 1991 Sep;9(9):1714-5. doi: 10.1200/JCO.1991.9.9.1714. J Clin Oncol. 1991. PMID: 1875227 No abstract available.
Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.
Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood VE, Carducci M. Mahalingam D, et al. Among authors: kurman m. Br J Cancer. 2016 Apr 26;114(9):986-94. doi: 10.1038/bjc.2016.72. Br J Cancer. 2016. PMID: 27115568 Free PMC article. Clinical Trial.
A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Cavenagh J, Oakervee H, Baetiong-Caguioa P, Davies F, Gharibo M, Rabin N, Kurman M, Novak B, Shiraishi N, Nakashima D, Akinaga S, Yong K. Cavenagh J, et al. Among authors: kurman m. Br J Cancer. 2017 Oct 24;117(9):1295-1302. doi: 10.1038/bjc.2017.302. Epub 2017 Sep 5. Br J Cancer. 2017. PMID: 28873084 Free PMC article. Clinical Trial.
16 results